Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
5,016
datasets available to search
ShareScore release 0.9.0
Dataset results
5,016 results for “THERAPEUTICS”
Supplementary (MD): Repurposing Alzheimer's Therapeutics: A Computational Approach to Identifying Potential SARS-CoV-2 Mpro Inhibitors
<p>100 ns Molecular Dynamic Simulation Trajectories for Compound 2, 3, 6, 7, and 8 </p>
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations
<p>This study aims to investigate the accumulation of genomic instability and chromosome segregation errors after the acquisition of resistance to CDK4/6i in ER+ breast cancer and to test the efficacy of mitotic kinase inhibitors as a potential treatment for CDK4/6i-resistant breast cancer patients.</p> <p><strong>This repository contains whole-exome and shallow whole-genome sequencing from luminal breast cancer patient-derived organoid (BPTO.95 #1 and #2) both at the untreated or Parental state and post resistance to Palbociclib</strong>.</p> <p>Palbociclib resistance was developed by continuous dose-escalation of palbociclib up to 0.5-1 μM until cell growth was observed in the presence of the drug (10-12 months for PDO). During this time, parental cell lines and organoids were cultured in regular media to match the time spent in culture. Once resistance was established, Palbo-R PDOs were cultured in a regular growth medium without palbociclib. Cells were cultured without palbociclib for at least two weeks before evaluating resistance.</p>
On-line Solid Phase Extraction High Performance Liquid Chromatography Method Coupled with Tandem Mass Spectrometry for the Therapeutic Monitoring of Cannabidiol and 7-Hydroxy-cannabidiol in Human Serum and Saliva
<p>This database includes the raw data linked with the paper “On-line Solid Phase Extraction High Performance Liquid Chromatography Method Coupled with Tandem Mass Spectrometry for the Therapeutic Monitoring of Cannabidiol and 7-Hydroxy-cannabidiol in Human Serum and Saliva".</p> <p>Cannabidiol is a novel antiseizure medication approved in Europe and the US for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex. We describe in this article a new and simple liquid chromatography-mass spectrometry method (LC-MS/MS) for the determination of cannabidiol and its active metabolite 7-hydroxy-cannabidiol in microvolumes of serum and saliva (50 μL), to be used as a tool for therapeutic drug monitoring (TDM) and pharmacokinetic studies. After on-line solid phase extraction cannabidiol, 7-hydroxy-cannabidiol and the internal standard cannabidiol-d3 are separated on a monolithic C18 column under gradient conditions. Calibration curves are linear within the validated concentration range (10-1000 ng/mL for cannabidiol and 5-500 ng/mL for 7-hydroxy-cannabidiol).</p> <p>The method is accurate (intraday and interday accuracy within 94-112% for cannabidiol, 91-109% for 7-hydroxy-cannabidiol), precise (intraday and interday precision <11.6% for cannabidiol and <11.7% for 7- hydroxy-cannabidiol) and sensitive, with a LOQ of 2.5 ng/mL for cannabidiol and 5 ng/mL for 7-hydroxy-cannabidiol. The stability of the analytes was confirmed under different storage conditions. Extraction recoveries were in the range of 81-129% for cannabidiol and 100-113% for 7-hydroxy-cannabidiol.</p> <p>The applicability of the method to TDM was demonstrated by analysis of human serum and saliva samples obtained from patients with epilepsy treated with cannabidiol.</p>
Dataset related to article "Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer A Promising Therapeutic Approach"
<p>This record contains raw data related to article "Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer A Promising Therapeutic Approach"</p> <p>OBJECTIVE:</p> <p>Stereotactic body radiation therapy (SBRT) has been successfully used to treat oligometastases of several primary tumors, but few experiences have been described in patients with gynecological oligometastatic cancer, particularly in ovarian neoplasm. The aim of this study was to evaluate the role of this new radiotherapy modality in a series of oligometastatic ovarian cancer patients.</p> <p>MATERIALS AND METHODS:</p> <p>Clinical records of patients affected by oligometastatic ovarian carcinoma treated with SBRT were reviewed.</p> <p>RESULTS:</p> <p>Twenty-six patients with 44 metastatic lesions (lymph nodes, 63.6%; liver, 31.8%; and lung, 4.5%) treated with SBRT between January 2011 and May 2017 were analyzed. After a median follow-up period of 28.5 months (range, 6-86 months), 17 patients (65.4%) were still alive at time of analysis: 6 are without evidence of disease, 11 experienced a disease progression. Eight patients died of disease, 1 died because of an heart attack while being disease free. The median local control (LC) was not reached. One-, 2-, and 5-year LCs were 92.9%. Median progression-free survival was 19 months, with 1-year progression-free survival of 69.3% and 38% at 2 years, 19% at 5 years. Median overall survival was 64.5 months, with all patients alive after 1 year, 92.7% at 2 years, and 61.7% at 5 years. Five (11.3%) cases experienced G2 toxicity; most common adverse effect was nausea and vomiting (3 cases [6.8%]) followed by abdominal pain (2 cases [4.5%]). None of the patients had grade 3 or grade 4 acute or late toxicity.</p> <p>CONCLUSIONS:</p> <p>In conclusion, SBRT is a feasible and safe approach for selected cases of oligometastatic ovarian cancer, with satisfactory results in terms of LC and disease free survival.</p> <p> </p>
Weighing up the potential of "superfoods" in enhancing established therapeutical approaches for periodontal disease
<p>Dataset for all analyses in the study.</p>
Therapeutic Salivary Monitoring of Perampanel in Patients with Epilepsy Using a Volumetric Absorptive Microsampling Technique
<p>Introduction</p> <p>This database includes the raw data linked with the paper “ Therapeutic Salivary Monitoring of Perampanel in Patients with Epilepsy Using a Volumetric Absorptive Microsampling Technique” published in “pharmaceutics”.</p> <p>The present work describes the development and validation of a volumetric absorptive microsampling (VAMS) method combined with liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) for the quantitative determination of the antiseizure medication perampanel in oral fluid and its clinical applicability in patients with epilepsy. VAMS tips were loaded with 30 μL of oral fluid, dried for 60 minutes and placed into clean tubes. Analytes were extracted with methanol and the samples were incubated at 50°C, sonicated and centrifuged. The supernatant was evaporated at room temperature under a gentle stream of nitrogen and reconstituted with 60 μL of methanol. Separation and quantification were achieved on a monolithic column connected to a mass spectrometer. Calibration curves were linear between 0.5 and 300 ng/mL. Intra- and inter-day accuracy was within 85.6-103.2% and intra-day and inter-day precision did not exceed 12.1%. Mean extraction recoveries ranged from 81.3% to 98.7%. Perampanel was stable in samples collected by VAMS and stored under different storage conditions. The developed VAMS-LC-MS/MS method was validated according to internationally accepted criteria and showed adequate bioanalytical performances holding great potential as alternative strategy to support domiciliary TDM in patients with epilepsy treated with perampanel according to the simplicity of samples collection.</p>
Transition metal ions as a new therapeutic target for cardiac light chain amyloidosis
<p>This dataset comprises raw data related to the study “Transition metal ions as a new therapeutic target for cardiac light chain amyloidosis”, aimed at investigating the <em>in vitro </em>and <em>in vivo</em> role of transition metal ions in the redox process underlying LC cardiotoxicity. This research was funded by Italian Ministry of Health (Ricerca Finalizzata RF-2016-02361756 to Prof. Giovanni Palladini).</p>
Raw data for "Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration. Eur J Clin Pharmacol. 2023;79:1173-1184." and "Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways;Drugs R D. 2023 Sep 13. doi: 10.1007/s40268-023-00438-2."
<p><strong>Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways:</strong></p> <p><strong>Background and objective: </strong>N-terminal pro-B-type natriuretic peptide (NT-proBNP) and soluble interleukin 1 receptor-like 1 ST2 (sST2) are biomarkers used to grade heart failure with reduced ejection fraction (HFrEF) severity. Both are potential targets of HFrEF treatment, but the first is associated with the patient's hemodynamic status, while the second is more indicative of the inflammatory status and of myocardial fibrosis. The aim of this study was to assess the kinetics of these biomarkers after treatment with sacubitril/valsartan in HFrEF.</p> <p><strong>Methods: </strong>We analyzed blood samples of patients with HFrEF at baseline (before sacubitril/valsartan treatment), after 1, 2, and 3 months (respectively, after a month taking the 24/26 - 49/51 - 97/103 mg twice daily, or b.i.d., doses), and 6 months after the maximum-tolerated dose was reached (end study).</p> <p><strong>Results: </strong>We obtained samples from 72 patients with HFrEF (age 64.0 ± 10.5 years, 83% males). NT-proBNP and sST2 values progressively and significantly reduced to 37% and 16%, respectively, with a greater reduction for NT-proBNP (p < 0.001). Specifically, NT-proBNP reduced from 1144 [593-2586] pg/mL to 743 [358-1524] pg/mL and sST2 from 27.3 [20.5-35.0] ng/mL to 23.1 [15.9-30.7] ng/mL, p for trend < 0.001 in both cases. The reduction of the two biomarkers over time occurred with statistically significant different kinetics: deferred for sST2 and faster for NT-proBNP. No significant changes in renal function and potassium levels were recorded.</p> <p><strong>Conclusion: </strong>These findings suggest that, in patients with HF, sacubitril/valsartan effects on the cardiovascular system share a double pathway: a first, hemodynamic, faster pathway and a second, non-hemodynamic anti-fibrotic, delayed one. Both likely contribute to the sacubitril/valsartan benefits in HFrEF.</p> <p> </p> <p><strong>Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration</strong></p> <p><strong>Purpose: </strong>Sacubitril/valsartan is a mainstay of the treatment of heart failure with reduced ejection fraction (HFrEF); however, its effects on exercise performance yielded conflicting results. Aim of our study was to evaluate the impact of sacubitril/valsartan on exercise parameters and echocardiographic and biomarker changes at different drug doses.</p> <p><strong>Methods: </strong>We prospectively enrolled consecutive HFrEF outpatients eligible to start sacubitril/valsartan. Patients underwent clinical assessment, cardiopulmonary exercise test (CPET), blood sampling, echocardiography, and completed the Kansas City Cardiomyopathy Questionnaire (KCCQ-12). Sacubitril/valsartan was introduced at 24/26 mg b.i.d. dose and progressively uptitrated in a standard monthly-based fashion to 97/103 mg b.i.d. or maximum tolerated dose. Study procedures were repeated at each titration visit and 6 months after reaching the maximum tolerated dose.</p> <p><strong>Results: </strong>Ninety-six patients completed the study, 73 (75%) reached maximum sacubitril/valsartan dose. We observed a significant improvement in functional capacity across all study steps: oxygen intake increased, at peak exercise (from 15.6 ± 4.5 to 16.5 ± 4.9 mL/min/kg; p trend = 0.001), while minute ventilation/carbon dioxide production relationship reduced in patients with an abnormal value at baseline. Sacubitril/valsartan induced positive left ventricle reverse remodeling (EF from 31 ± 5 to 37 ± 8%; p trend < 0.001), while NT-proBNP reduced from 1179 [610-2757] to 780 [372-1344] pg/ml (p trend < 0.0001). NYHA functional class and the subjective perception of limitation in daily life at KCCQ-12 significantly improved. The Metabolic Exercise Cardiac Kidney Index (MECKI) score progressively improved from 4.35 [2.42-7.71] to 2.35% [1.24-4.96], p = 0.003.</p> <p><strong>Conclusions: </strong>A holistic and progressive HF improvement was observed with sacubitril/valsartan in parallel with quality of life. Likewise, a prognostic enhancement was observed.</p>
Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic
ClinicalTrials.gov study NCT03395769. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic
ClinicalTrials.gov study NCT03395743. IPD Sharing: Not stated. Countries: 0. Publications: 0.
CTHRC1 is a new therapeutic target and serum diagnostic biomarker for aortic dissection
GEO Series GSE298176. Mus musculus. 54 samples. Type: Expression profiling by high throughput sequencing.
Arthritis pathogenesis: Development of novel diagnostic and therapeutic approaches
GEO Series GSE27358. Homo sapiens; Mus musculus. 4 samples. Type: Expression profiling by array.
Baseline serum anti-glycan total Ig antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
GEO Series GSE50236. Quercus alba; Gossypium hirsutum; Pandalus borealis; Homo sapiens; Medicago sativa; Gallus gallus; Ovis aries; Megathura crenulata; Frangula alnus; Rhodotorula; Bos taurus; Mus musculus; Bothrops moojeni; Senegalia senegal; Pachymenia carnosa; Dermestes lardarius. 113 samples. Type: Protein profiling by protein array.
N6-methyladenosine reader YTHDF1 promotes stemness and therapeutic resistance in hepatocellular carcinoma by enhancing NOTCH1 expression
GEO Series GSE252752. Homo sapiens. 22 samples. Type: Expression profiling by high throughput sequencing; Other.
Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance.
GEO Series GSE98815. Homo sapiens. 72 samples. Type: Expression profiling by high throughput sequencing; Methylation profiling by array.
Cellular senescence in skeletal muscle aging: new mechanisms and therapeutic potential for sarcopenia [cut&run_seq_IMR90]
GEO Series GSE268431. Homo sapiens. 2 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Bone marrow stromal cell antigen 2 is a novel therapeutic target of glioblastoma stem cells
GEO Series GSE85024. Homo sapiens. 2 samples. Type: Expression profiling by array.
A Time-dependent Glia cell-Mediated Neuroprotective Effects of Kv7/KCNQ channel opener QO-83 in Ischemic Stroke: Mechanisms of Action and Therapeutic Potential
GEO Series GSE244576. Mus musculus. 5 samples. Type: Expression profiling by high throughput sequencing.
Therapeutic vaccine induced plasma cell differentiation is defective upon persistent HBsAg stimulation [scRNA]
GEO Series GSE230862. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Targeting oncogenic BCR signaling therapeutically by glucocorticoids and CSK inhibition
GEO Series GSE225858. Homo sapiens. 83 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.